Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: 75045-07-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: sufficient documented and scientifically acceptable
Data source
Reference
- Reference Type:
- publication
- Title:
- Toxicokinetic study of 2-mercaptobenzimidazole (MBI) and its methylated derivative (MMBI) in rats treated by repeated oral administration - metabolism and urinary excretion
- Author:
- Tsuda M, Sakemi K, Ito R, Usami M, Ohno Y
- Year:
- 1 997
- Bibliographic source:
- J Toxicol Sci 22, 348
Materials and methods
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- Male Wistar rats were treated with 0.3 mmol/kg of MBI (2-mercaptobenzimidazole) or MMBI (2mercaptomethylbenzimidazole) by gavage for 15 days. 24h-urine samples were collected on day(s) 1, 8 and 15. Urinary amounts of MBI and MMBI, and their metabolites were determined.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione
- EC Number:
- 258-904-8
- EC Name:
- 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione
- Cas Number:
- 53988-10-6
- Molecular formula:
- C8H8N2S
- IUPAC Name:
- 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione
- Details on test material:
- MMBI (methylated derivative of 2-mercaptobenzimidazole), no further data
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Duration and frequency of treatment / exposure:
- 15 days
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.3 mmol/kg = 49.27 mg
- No. of animals per sex per dose / concentration:
- no data
- Control animals:
- not specified
Results and discussion
- Preliminary studies:
- no data
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- In the MMBI treatment, the urinary amounts were MMBI < MBI (methylbenzimidazoles) (4 fold in day 1) and this ratio was not changed significantlly in days 8 and 15. The 2 isomeres of MMBI were desulfurized and excreted in different extent.
Any other information on results incl. tables
In the MMBI treatment the, the urinary amounts were MMBI < MBI (4 fold in day 1) and this ratio was not changed significantly in days 8 and 15. The 2 isomers of MMBI were desulfurized and excreted in different extend.
The effective desulfurization in MMBI may be a causal factor for the lack of thyroid toxicity
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
- Executive summary:
Wistar male rats were treated with 0.3 mmol/kg of MBI (2-mercaptobenzimidazole) or MMBI (methylated derivative of 2-mercaptobenzimidazole) by gavage for 15 days and collected 24h-urine samples (n=3) in day(s) 1, 8, and 15. Urinary amounts of MBI and MMBI, and their metabolites were determined.
In the MMBI treatment, the urinary amounts were MMBI < MBI (methylbenzimidazoles) (4 fold in day 1) and this ratio was not changed significantlly in days 8 and 15. The 2 isomeres of MMBI were desulfurized and excreted in different extent. The effective desulfurization in MMBI may be a causal factor for the lack of thyroid toxicity
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.